EL7.AI
StocksMediumUpdated•Originally published 5 November 2026•Updated 5 November 2026•
1 min read

ADMA Biologics Hits 10-Month High Following Q3 Earnings Beat

Key Facts

1ADMA Biologics raised its minimum 2026 adjusted EBITDA guidance to at least $275 million.
2The company reiterated its 2026 revenue guidance of at least $530 million.
3The guidance raise is driven by accelerating demand for the company's ASCENIV product.

ADMA Biologics shares reached a 10-month high after the company's third-quarter earnings exceeded market expectations. The beat was driven by robust sales growth of its Asceniv product, according to reports on the quarterly performance.

The company simultaneously increased its 2026 adjusted EBITDA floor to at least $275 million. Seeking Alpha reported that ADMA Biologics reiterated its revenue guidance for the same period at a minimum of $530 million, reflecting an expansion in operating margins.

ADMA closed at $10.48 on November 4, 2026, having reached a session high of $11.49 against a low of $10.25. The move to 10-month highs highlights investor reaction to accelerating demand for the company's core offerings and its upgraded long-term profitability outlook.

Open on chart